Business:
Stereopure oligonucleotides
Drug notes:
WVE-003 Clin1/Clin2 Huntington's disease (partner: Takeda); WVE-N531 Clin1/Clin2 DMD; WVE-006 Clin0 AATD - lung & liver disease; 3 undisclosed programs Clin0 spinocerebellar ataxia 3, CNS diseases
About:
Wave Life Sciences is developing novel oligonucleotide therapies for the treatment of rare genetic diseases. The company's PRISM platform enables the precise design, optimization, and production of stereopure oligonucleotides. Unlike traditional oligonucleotides, which are racemic mixtures of stereoisomers, stereopure oligonucleotides are composed of only one stereoisomer. This makes stereopure oligonucleotides more potent and less toxic than traditional oligonucleotides. Wave Life Sciences is using its PRISM platform to develop stereopure oligonucleotide therapies for a variety of rare genetic diseases, including Huntington's disease, Duchenne muscular dystrophy, and Batten disease. The company's lead product candidate, WVE-001, is a stereopure oligonucleotide therapy for the treatment of Huntington's disease.
Senior Manager, Medical Editing Lexington, MA|6 days ago
Associate Director, Regulatory Affairs Lexington, MA|7 days ago
Research Associate I/II, Formulation and Analytica... Lexington, MA|7 days ago
Analytical Scientist II/QC Manager, External Opera... Lexington, MA|8 days ago
Director, Clinical Operations (UK) United Kingdom|8 days ago
Scientist I, Process Development Lexington, MA|10 days ago
Scientist I, Analytical Lexington, MA|10 days ago
Postdoctoral Researcher (RNA Biology) Cambridge, MA|37 days ago
Raw Material Planner I Lexington, MA|77 days ago
Director/Sr. Director, Corporate Communications Cambridge, MA|Not provided
Associate Director, Drug Product Technical Service... Lexington, MA|Not provided